ENZALUTAMIDE, DOCETAXEL, ABIRATERONE
RADAR-1 CRPC
Approved small_molecule active
Quick answer
ENZALUTAMIDE, DOCETAXEL, ABIRATERONE for metastatic castration resistant prostate cancer without mutations of BRCA1/2 genes or unknown is a Approved program (small_molecule) at Fondazione Telethon ETS with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Fondazione Telethon ETS
- Indication
- metastatic castration resistant prostate cancer without mutations of BRCA1/2 genes or unknown
- Phase
- Approved
- Modality
- small_molecule
- Status
- active